"Simple is best", as Quotient plans US advance with Quo-Test POC diabetes test
This article was originally published in Clinica
UK firm Quotient Diagnostics, a small company formed three years ago to exploit technology licensed from Barts and the London NHS trust, is preparing for US launch of its first product, an A1c test, in mid-2007.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.